BACKGROUND: Severe combined immunodeficiency due to adenosine deaminase (ADA) deficiency (ADA-SCID) is a rare and life-threatening primary immunodeficiency. METHODS: We treated 50 patients with ADA-SCID (30 in the United States and 20 in the United Kingdom) with an investigational gene therapy composed of autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) transduced ex vivo with a self-inactivating lentiviral vector encoding human ADA. Data from the two U.S. studies (in which fresh and cryopreserved formulations were used) at 24 months of follow-up were analyzed alongside data from the U.K. study (in which a fresh formulation was used) at 36 months of follow-up. RESULTS: Overall survival was 100% in all studies up to 24 and 36 months. Event-free survival (in the absence of reinitiation of enzyme-replacement therapy or rescue allogeneic hematopoietic stem-cell transplantation) was 97% (U.S. studies) and 100% (U.K. study) at 12 months; 97% and 95%, respectively, at 24 months; and 95% (U.K. study) at 36 months. Engraftment of genetically modified HSPCs persisted in 29 of 30 patients in the U.S. studies and in 19 of 20 patients in the U.K. study. Patients had sustained metabolic detoxification and normalization of ADA activity levels. Immune reconstitution was robust, with 90% of the patients in the U.S. studies and 100% of those in the U.K. study discontinuing immunoglobulin-replacement therapy by 24 months and 36 months, respectively. No evidence of monoclonal expansion, leukoproliferative complications, or emergence of replication-competent lentivirus was noted, and no events of autoimmunity or graft-versus-host disease occurred. Most adverse events were of low grade. CONCLUSIONS: Treatment of ADA-SCID with ex vivo lentiviral HSPC gene therapy resulted in high overall and event-free survival with sustained ADA expression, metabolic correction, and functional immune reconstitution. (Funded by the National Institutes of Health and others; ClinicalTrials.gov numbers, NCT01852071, NCT02999984, and NCT01380990.).
BACKGROUND: Severe combined immunodeficiency due to adenosine deaminase (ADA) deficiency (ADA-SCID) is a rare and life-threatening primary immunodeficiency. METHODS: We treated 50 patients with ADA-SCID (30 in the United States and 20 in the United Kingdom) with an investigational gene therapy composed of autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) transduced ex vivo with a self-inactivating lentiviral vector encoding human ADA. Data from the two U.S. studies (in which fresh and cryopreserved formulations were used) at 24 months of follow-up were analyzed alongside data from the U.K. study (in which a fresh formulation was used) at 36 months of follow-up. RESULTS: Overall survival was 100% in all studies up to 24 and 36 months. Event-free survival (in the absence of reinitiation of enzyme-replacement therapy or rescue allogeneic hematopoietic stem-cell transplantation) was 97% (U.S. studies) and 100% (U.K. study) at 12 months; 97% and 95%, respectively, at 24 months; and 95% (U.K. study) at 36 months. Engraftment of genetically modified HSPCs persisted in 29 of 30 patients in the U.S. studies and in 19 of 20 patients in the U.K. study. Patients had sustained metabolic detoxification and normalization of ADA activity levels. Immune reconstitution was robust, with 90% of the patients in the U.S. studies and 100% of those in the U.K. study discontinuing immunoglobulin-replacement therapy by 24 months and 36 months, respectively. No evidence of monoclonal expansion, leukoproliferative complications, or emergence of replication-competent lentivirus was noted, and no events of autoimmunity or graft-versus-host disease occurred. Most adverse events were of low grade. CONCLUSIONS: Treatment of ADA-SCID with ex vivo lentiviral HSPC gene therapy resulted in high overall and event-free survival with sustained ADA expression, metabolic correction, and functional immune reconstitution. (Funded by the National Institutes of Health and others; ClinicalTrials.gov numbers, NCT01852071, NCT02999984, and NCT01380990.).
Authors: Belinda Chan; Diane Wara; John Bastian; Michael S Hershfield; John Bohnsack; Colleen G Azen; Robertson Parkman; Kenneth Weinberg; Donald B Kohn Journal: Clin Immunol Date: 2005-08-22 Impact factor: 3.969
Authors: E Haddad; P Landais; W Friedrich; B Gerritsen; M Cavazzana-Calvo; G Morgan; Y Bertrand; A Fasth; F Porta; A Cant; T Espanol; S Müller; P Veys; J Vossen; A Fischer Journal: Blood Date: 1998-05-15 Impact factor: 22.113
Authors: Caroline Y Kuo; Elizabeth Garabedian; Jennifer Puck; Morton J Cowan; Kathleen E Sullivan; Rebecca H Buckley; Charlotte Cunningham-Rundles; Rebecca Marsh; Fabio Candotti; Donald B Kohn Journal: J Clin Immunol Date: 2020-09-02 Impact factor: 8.317
Authors: Linda M Griffith; Morton J Cowan; Luigi D Notarangelo; Jennifer M Puck; Rebecca H Buckley; Fabio Candotti; Mary Ellen Conley; Thomas A Fleisher; H Bobby Gaspar; Donald B Kohn; Hans D Ochs; Richard J O'Reilly; J Douglas Rizzo; Chaim M Roifman; Trudy N Small; William T Shearer Journal: J Allergy Clin Immunol Date: 2009-12 Impact factor: 10.793
Authors: Claudia A Montiel-Equihua; Lin Zhang; Sean Knight; Heba Saadeh; Simone Scholz; Marlene Carmo; Maria E Alonso-Ferrero; Michael P Blundell; Aiste Monkeviciute; Reiner Schulz; Mary Collins; Yasuhiro Takeuchi; Manfred Schmidt; Lynette Fairbanks; Michael Antoniou; Adrian J Thrasher; H Bobby Gaspar Journal: Mol Ther Date: 2012-03-20 Impact factor: 11.454
Authors: Denise A Carbonaro; Lin Zhang; Xiangyang Jin; Claudia Montiel-Equihua; Sabine Geiger; Marlene Carmo; Aaron Cooper; Lynette Fairbanks; Michael L Kaufman; Neil J Sebire; Roger P Hollis; Michael P Blundell; Shantha Senadheera; Pei-Yu Fu; Arineh Sahaghian; Rebecca Y Chan; Xiaoyan Wang; Kenneth Cornetta; Adrian J Thrasher; Donald B Kohn; H Bobby Gaspar Journal: Mol Ther Date: 2013-11-20 Impact factor: 11.454
Authors: Steven J Howe; Marc R Mansour; Kerstin Schwarzwaelder; Cynthia Bartholomae; Michael Hubank; Helena Kempski; Martijn H Brugman; Karin Pike-Overzet; Stephen J Chatters; Dick de Ridder; Kimberly C Gilmour; Stuart Adams; Susannah I Thornhill; Kathryn L Parsley; Frank J T Staal; Rosemary E Gale; David C Linch; Jinhua Bayford; Lucie Brown; Michelle Quaye; Christine Kinnon; Philip Ancliff; David K Webb; Manfred Schmidt; Christof von Kalle; H Bobby Gaspar; Adrian J Thrasher Journal: J Clin Invest Date: 2008-09 Impact factor: 14.808
Authors: Robert N Plasschaert; Mark P DeAndrade; Fritz Hull; Quoc Nguyen; Tara Peterson; Aimin Yan; Mariana Loperfido; Cristina Baricordi; Luigi Barbarossa; John K Yoon; Yildirim Dogan; Zeenath Unnisa; Jeffrey W Schindler; Niek P van Til; Luca Biasco; Chris Mason Journal: Mol Ther Date: 2022-05-25 Impact factor: 12.910
Authors: Bryanna Reinhardt; Omar Habib; Kit L Shaw; Elizabeth Garabedian; Denise A Carbonaro-Sarracino; Dayna Terrazas; Beatriz Campo Fernandez; Satiro De Oliveira; Theodore B Moore; Alan K Ikeda; Barbara C Engel; Gregory M Podsakoff; Roger P Hollis; Augustine Fernandes; Connie Jackson; Sally Shupien; Suparna Mishra; Alejandra Davila; Jack Mottahedeh; Andrej Vitomirov; Wenzhao Meng; Aaron M Rosenfeld; Aoife M Roche; Pascha Hokama; Shantan Reddy; John Everett; Xiaoyan Wang; Eline T Luning Prak; Kenneth Cornetta; Michael S Hershfield; Robert Sokolic; Suk See De Ravin; Harry L Malech; Frederic D Bushman; Fabio Candotti; Donald B Kohn Journal: Blood Date: 2021-10-14 Impact factor: 25.476
Authors: Karyl S Barron; Ivona Aksentijevich; Natalie T Deuitch; Deborah L Stone; Patrycja Hoffmann; Ryan Videgar-Laird; Ariane Soldatos; Jenna Bergerson; Camilo Toro; Cornelia Cudrici; Michele Nehrebecky; Tina Romeo; Anne Jones; Manfred Boehm; Jennifer A Kanakry; Dimana Dimitrova; Katherine R Calvo; Hawwa Alao; Devika Kapuria; Gil Ben-Yakov; Dominique C Pichard; Londa Hathaway; Alessandra Brofferio; Elisa McRae; Natalia Sampaio Moura; Oskar Schnappauf; Sofia Rosenzweig; Theo Heller; Edward W Cowen; Daniel L Kastner; Amanda K Ombrello Journal: Front Immunol Date: 2022-01-10 Impact factor: 7.561
Authors: Christina Fichter; Anupriya Aggarwal; Andrew Kam Ho Wong; Samantha McAllery; Vennila Mathivanan; Bailey Hao; Hugh MacRae; Melissa J Churchill; Paul R Gorry; Michael Roche; Lachlan R Gray; Stuart Turville Journal: Viruses Date: 2021-06-18 Impact factor: 5.048